Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961263 | 1.00 | FFAR4 (0.56) | FFAR4ALDH1A1CYP3A4L3MBTL1RAB9A | |
| SCHEMBL5958670 | 0.85 | ALDH1A1 (0.48) | FFAR4ALDH1A1CYP3A4L3MBTL1RAB9A | |
| SCHEMBL9385964 | 0.84 | ALDH1A1 (0.52) | FFAR4ALDH1A1CYP3A4L3MBTL1RAB9A | |
| SCHEMBL710315 | 0.83 | NR4A1 (0.54) | FFAR4ALDH1A1L3MBTL1RAB9AMAPT | |
| SCHEMBL8146457 | 0.82 | NR4A1 (0.52) | FFAR4ALDH1A1CYP3A4L3MBTL1RAB9A | |
| SCHEMBL16372579 | 0.82 | ALDH1A1 (0.53) | FFAR4ALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL4628852 | 0.81 | EPHX2 (0.46) | EPHX2PGRARCYP11B1CYP11B2 | |
| SCHEMBL3722072 | 0.80 | FFAR4 (0.56) | FFAR4CYP3A4RAB9AKDM4EGAA | |
| SCHEMBL197560 | 0.79 | FFAR4 (0.43) | FFAR4ALDH1A1KMT2ASMN1; SMN2AR | |
| SCHEMBL4230857 | 0.79 | KMT2A (0.54) | FFAR4ALDH1A1CYP3A4L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3796905-B1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | UNIV ILLINOIS (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-10 | — | — | US | disclosed |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4326723-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177975-A | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| US-20230357161-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-09 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2007016353-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRIDO[4,3,B]INDOLES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| US-6835745-B2 | Treating or inhibiting osteoporosis or bone demineralization, inflammatory bowel disease, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometriosis, endometrial cardiovascular disease, Alzheimer's disease | WYETH | 2004-12-28 | — | — | US | disclosed |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| US-5304554-A | Intercalators of DNA, inhibit replication of retroviruses | EMORY UNIVERSITY (US) | 1994-04-19 | — | — | US | disclosed |
| US-4879398-A | Process for producing 2,6-disubstituted tyrosine | MONSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
| US-4218373-A | FOR DYEING WOOL AND POLYAMIDES, DEEP RED TO VIOLET | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027178-A1 | Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists | HTR2B, HTR1A, HTR3B | FFAR4 73/4885ALDH1A1 1702/4885CYP3A4 265/4885 |
| US-12286407-B2 | Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases | ESR2, ESRRG, GPER1 | FFAR4 276/4885ALDH1A1 1027/4885CYP3A4 1246/4885 |
| US-11993591-B2 | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | HAVCR2, CYP7A1, CYP26B1 | FFAR4 2126/4885ALDH1A1 629/4885CYP3A4 17/4885 |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | ESR2, ESR1, GPER1 | FFAR4 293/4885ALDH1A1 1071/4885CYP3A4 376/4885 |
| US-20230357161-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | FFAR4 276/4885ALDH1A1 1027/4885CYP3A4 1246/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | FFAR4 2861/4885ALDH1A1 1786/4885CYP3A4 2214/4885 |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | FFAR4 3920/4885ALDH1A1 1620/4885CYP3A4 1178/4885 |
| US-20250223264-A1 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | ESR2, ESRRG, GPER1 | FFAR4 276/4885ALDH1A1 1027/4885CYP3A4 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.